LYMPHOBLASTIC LYMPHOMA

This study aims to see if adding a nutrient called levocarnitine to standard chemotherapy can prevent severe liver damage in teenagers and young adults (ages 15-39) being treated for leukemia or lymphoma. A key chemotherapy drug, asparaginase, often causes liver toxicity, which c…

This study is testing the safety and effectiveness of a new drug, recombinant Erwinia asparaginase, when combined with standard chemotherapy for adults with newly diagnosed, high-risk acute lymphoblastic leukemia or lymphoblastic lymphoma. The trial will enroll 53 adults aged 18-…

This study is testing a new smartphone app designed to help teenagers and young adults with leukemia remember to take their daily oral chemotherapy pills. The app sends personalized reminders and checks in on how patients are feeling. Researchers want to see if the app is easy to…

This study is testing a combination of several chemotherapy drugs, with or without an antibody drug, plus a targeted pill called ponatinib. It aims to see if this approach is safe and effective for adults newly diagnosed with a specific, aggressive form of leukemia or lymphoma. T…

This study is testing a specific type of stem cell transplant using donated umbilical cord blood to treat patients with serious blood cancers and disorders. The procedure involves high-dose chemotherapy and radiation to wipe out the patient's diseased bone marrow before infusing …

This study is testing a stem cell transplant from a partially matched family donor for patients with hard-to-treat blood cancers like leukemia and lymphoma. Before the transplant, patients receive chemotherapy and radiation to wipe out their own bone marrow and cancer cells. The …

This study is testing a new type of cell therapy called WU-CART-007 for people with T-cell leukemia or lymphoma that has come back or hasn't responded to other treatments. The therapy uses donor immune cells engineered to attack cancer cells. The main goal is to see if it can put…

This trial is testing whether adding two targeted immunotherapies, inotuzumab and blinatumomab, to standard chemotherapy can better control leukemia in children and young adults. It aims to see if this combination helps more patients achieve deep remission with minimal detectable…

This study is testing a personalized cell therapy for adults with advanced B-cell leukemias that have not responded to standard drugs. Doctors take a patient's own immune cells, modify them in a lab to target a protein (CD19) found on their cancer cells, and then infuse them back…

This study is testing whether removing a specific type of immune cell (called naive T cells) from a donor's stem cells before transplant can prevent chronic graft-versus-host disease in children and young adults with blood cancers. Chronic graft-versus-host disease is a serious c…

This study is testing a new method to help patients recover their immune systems faster after a stem cell transplant for leukemia. It involves giving patients a special, filtered portion of their donor's immune cells, aiming to reduce the risk of life-threatening viral and fungal…

This early-stage study is testing whether an experimental drug called LP-118 can be safely combined with an approved leukemia drug, ponatinib, and standard chemotherapy. The goal is to find the safest and most effective dose for patients whose T-cell acute lymphoblastic leukemia …

This early-stage trial is testing a new vaccine designed to prevent serious cytomegalovirus (CMV) infections. The study involves patients with blood cancers who are receiving a stem cell transplant from a partially matched donor, a procedure that carries a high risk of CMV. Resea…

This study aims to understand why children and young adults with cancer in low- and middle-income countries often have worse outcomes than those in wealthier nations. Researchers will look back at the medical records of up to 18,000 patients to identify patterns of treatment fail…

This study aims to collect the detailed information doctors need to choose the most appropriate treatment plan for children newly diagnosed with certain types of acute leukemia. Children aged 1-18 will receive 7 days of initial chemotherapy while their cancer cells are tested. Th…